The management of severe hyponatraemia is a challenging task for intensivists. It should be based on underlying pathophysiology, especially the duration of hyponatraemia (acute vs. chronic) and the presence or absence of severe neurologic symptoms. We describe a case of severe community-acquired hyponatraemia in which central pontine myelinolysis developed several days after discharge from the intensive care unit, despite a gradual increase of plasma sodium levels during the intensive care unit stay.
MoritzM.L., AyusJ.C.The pathophysiology and treatment of hyponatraemic encephalopathy: an update. Nephrol Dial Transplant2003; 18: 2486–2491.
2.
SedlacekM., SchoolwerthA.C., RemillardB.D.Electrolyte disturbances in the intensive care unit. Semin Dial2006; 19: 496–501.
3.
SternsR.H., CappuccioJ.D., SilverS.M., CohenE.P.Neurologic sequelae after treatment of severe hyponatremia: a multicenter perspective. J Am Soc Nephrol1994; 4: 1522–1530.
4.
AdrogueH.J.Consequences of inadequate management of hyponatremia. Am J Nephrol2005; 25: 240–249.
5.
TisdallM., CrockerM., WatkissJ., SmithM.Disturbances of sodium in critically ill adult neurologic patients: a clinical review. J Neurosurg Anesthesiol2006; 18: 57–63.
6.
BattisonC., AndrewsP.J., GrahamC., PettyT.Randomized, controlled trial on the effect of a 20% mannitol solution and a 7.5% saline/6% dextran solution on increased intracranial pressure after brain injury. Crit Care Med2005; 33: 196–202.
7.
LienY.H., ShapiroJ.I.Hyponatremia: clinical diagnosis and management. Am J Med2007; 120: 653–658.
8.
AyusJ.C., ArieffA.I.Chronic hyponatremie encephalopathy in postmenopausal women: association of therapies with morbidity and mortality. JAMA1999; 281: 2299–2304.
9.
NzerueC.M., Baffoe-BonnieH., YouW., FalanaB., DaiS.Predictors of outcome in hospitalized patients with severe hyponatremia. J Natl Med Assoc2003; 95: 335–343.
10.
AchingerS.G., MoritzM.L., AyusJ.C.Dysnatremias: why are patients still dying?South Med J2006; 99: 353–362.
GhaliJ.K., KorenM.J., TaylorJ.R., Brooks-AsplundE., FanK., LongW.A.Efficacy and safety of oral conivaptan: a V1A/V2 vasopressin receptor antagonist, assessed in a randomized, placebo-controlled trial in patients with euvolemic or hypervolemic hyponatremia. J Clin Endocrinol Metab2006; 91: 2145–2152.
13.
SakamotoE., HagiwaraD., MorishitaY., TsukiyamaK., KondoK., YamamotoM.[Complete recovery of central pontine myelinolysis by high dose pulse therapy with methylprednisolone]. Nippon Naika Gakkai Zasshi2007; 96: 2291–2293.
14.
WangW.T., ChenY.Y., WuS.L., WeiT.S., LiuS.Y.Zolpidem dramatically improved motor and speech function in a patient with central pontine myelinolysis. Eur J Neurol2007; 14: e9–10.
15.
BiblD., LarnplC., GabrielC., JunglingG., BrockH., KostlerG.Treatment of central pontine myelinolysis with therapeutic plasmapheresis. Lancet1999; 353: 1155.
16.
GrimaldiD., CavalleriF., ValloneS., MilantiG., CortelliP.Plasmapheresis improves the outcome of central pontine myelinolysis. J Neurol2005; 252: 734–735.
